000			02084 a2200637 4500
005			20250517012425.0
264		0	_c20160509
008			201605s 0 0 eng d
022			_a1468-3288
024	7		_a10.1136/gutjnl-2014-308546 _2doi
040			_aNLM _beng _cNLM
100	1		_aFan, Rong
245	0	0	_aBaseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. _h[electronic resource]
260			_bGut _cFeb 2016
300			_a313-20 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aCohort Studies
650	0	4	_aFemale
650	0	4	_aHepatitis B Antibodies _xanalysis
650	0	4	_aHepatitis B e Antigens _ximmunology
650	0	4	_aHepatitis B, Chronic _ximmunology
650	0	4	_aHumans
650	0	4	_aInterferon-alpha _xtherapeutic use
650	0	4	_aMale
650	0	4	_aNucleosides _xtherapeutic use
650	0	4	_aPolyethylene Glycols _xtherapeutic use
650	0	4	_aRecombinant Proteins _xtherapeutic use
650	0	4	_aRetrospective Studies
650	0	4	_aSensitivity and Specificity
650	0	4	_aSeroconversion
700	1		_aSun, Jian
700	1		_aYuan, Quan
700	1		_aXie, Qing
700	1		_aBai, Xuefan
700	1		_aNing, Qin
700	1		_aCheng, Jun
700	1		_aYu, Yanyan
700	1		_aNiu, Junqi
700	1		_aShi, Guangfeng
700	1		_aWang, Hao
700	1		_aTan, Deming
700	1		_aWan, Mobin
700	1		_aChen, Shijun
700	1		_aXu, Min
700	1		_aChen, Xinyue
700	1		_aTang, Hong
700	1		_aSheng, Jifang
700	1		_aLu, Fengmin
700	1		_aJia, Jidong
700	1		_aZhuang, Hui
700	1		_aXia, Ningshao
700	1		_aHou, Jinlin
773	0		_tGut _gvol. 65 _gno. 2 _gp. 313-20
856	4	0	_uhttps://doi.org/10.1136/gutjnl-2014-308546 _zAvailable from publisher's website
999			_c24531362 _d24531362